Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 5, 2016

Ipsen to deploy Dassault Systèmes’ 3DEXPERIENCE platform to support drug discovery

French pharmaceutical company Ipsen has collaborated with Dassault Systèmes to develop new and effective programmes to support its drug discovery.

Dassault

French pharmaceutical company Ipsen has collaborated with Dassault Systèmes to develop new and effective programmes to support its drug discovery.

Under the terms, Ipsen will deploy Dassault’s 3DEXPERIENCE platform to accelerate its research and development (R&D), transformation and discovery of new therapeutic solutions.

The 3DEXPERIENCE platform is a business experience platform that is available on premises and in public or private cloud, Dassault said.

It offers data integration, modelling and simulation capabilities to better understand dysregulations linked to diseases.

The 3DEXPERIENCE platform also improves and shortens the identification of quality drug candidates.

Dassault Systèmes life sciences industry vice-president Jean Colombel said: "The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
"The 3DEXPERIENCE platform also improves and shortens the identification of quality drug candidates."

"Our partnership with Ipsen on the adoption of the 3DEXPERIENCE platform furthers the promise of the 3D experience approach by bridging life sciences disciplines and delivering innovative patient experiences."

The project also aims to optimise the R&D processes of Ipsen’s multi-disciplinary teams in the biotechnological and life sciences hubs in France, the UK and the US.

Ipsen R&D executive vice-president Claude Bertrand said: "After more than five years of partnering with Dassault Systèmes on the BioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools.

"Ipsen as a key scientific partner has open innovation in its DNA and this new collaborative and innovative digital platform will support Ipsen’s commitment to achieve therapeutic breakthroughs in patient care."

Ipsen primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders.


Image: 3DEXPERIENCE platform improves and shortens the identification of quality drug candidates. Photo: courtesy of Dassault Systèmes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU